Despite the presidential outcomes, we in the healthcare industry will still be faced with a heavy issue: how to go about reining in drug costs.
- Focus on adherence in real-world conditions.
Our C the Cure program for a cohort of hepatitis C patients co-infected with HIV resulted in 90% of the patients having a sustained virological response at 12 weeks post treatment. Did you know that this is only the second study to use this particular real-world data set known for co-infected HCV patients with this profile and treatment regimen? We need more studies like this.
- Streamline the prior authorization process (or until that happens, enlist the clinical pharmacist and their teams).
The lengthy conversation on prior authorizations has led to the conclusion that the cumbersome processes are here to stay. Providers will need to begin asking themselves certain questions:
- Do your PA forms go above and beyond what’s essential for assessment and completion?
- Are important data points on your PA forms made crystal clear to the clinicians or administrators who will be completing the forms?
The answer to both of these questions should be ‘yes.’
- Get ahead of the curve, especially as cancer trends toward a chronic condition.
Currently, there are 3,400 immunotherapy trials ongoing in the United States, over 14 million cancer patients are living longer, and ultra-high cost immunotherapeutics for multiple oncologic conditions are entering the market. As a result, we need to remember to talk about pricing. Pricing needs to be an important part of the discussion held among healthcare stakeholders, specifically before new specialty medications enter the market.
To read Marc’s full article, visit Managed Healthcare Executive.
To learn more about Curant Health, contact Senior Marketing Director, Kristin Lindsey, , at email@example.com.